Identification of a new STAT3 dimerization inhibitor through a pharmacophore-based virtual screening approach

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 31, Issue 6, 2016, Pages 1011-1017

  Poli, Giulio ^a   Gelain, Arianna ^b   Porta, Federica ^b   Asai, Akira ^c   Martinelli, Adriano ^a   Tuccinardi, Tiziano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Docking; pharmacophore model; STAT3; virtual screening

Indexed keywords

GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; PROTEIN INHIBITOR; PROTEIN SH2; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 DIMERIZATION INHIBITOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; STAT3 PROTEIN, HUMAN;

ARTICLE; CRYSTAL STRUCTURE; DIMERIZATION; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME STRUCTURE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; VIRTUAL REALITY; HUMAN; METABOLISM; PROTEIN CONFORMATION;

DIMERIZATION; HUMANS; PROTEIN CONFORMATION; STAT3 TRANSCRIPTION FACTOR;

EID: 84941365469     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2015.1079184     Document Type: Article

References (34)

1. J.E.DarnellJr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740−9
2. J.E.DarnellJr. STATs and gene regulation. Science 1997;277:1630−5
3. J.Turkson, R.Jove. STAT proteins:novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613−26
4. J.Bromberg, J.E.DarnellJr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468−73
5. J.Turkson. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409–22
6. D.Masciocchi, A.Gelain, S.Villa,. Signal Transducer and activator of transcription 3 (STAT3):a promising target for anticancer therapy. Future Med Chem 2011;3:367–97
7. B.Debnath, S.Xu, N.Neamati,. Small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) protein. J Med Chem 2012;55:6645−68
8. L.Costantino, D.Barlocco. STAT3 as a target for cancer drug discovery. Curr Med Chem 2008;15:834–43
9. H.Song, R.Wang, S.Wang, J.Lin. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102:4700−5
10. K.Siddiquee, S.Zhang, W.C.Guida,. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007;104:7391−6
11. K.Matsuno, Y.Masuda, Y.Uehara,. Identification of a new series of Stat3 inhibitors by virtual screening. ACS Med Chem Lett 2010;1:371−5
12. W.Hao, Y.Hu, C.Niu,. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg Med Chem Lett 2008;18:4988–92
13. X.Xu, M.M.Kasembeli, X.Jiang,. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One 2009;4:e4783–94
14. M.Zhang, W.Zhu, Y.Li. Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening. Eur J Med Chem 2013;62:301–10
15. L.J.Liu, K.H.Leung, D.S.Chan,. Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening. Cell Death Dis 2014;5:e1293–302
16. H.Chen, Z.Yang, C.Ding,. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur J Med Chem 2013;62:498–507
17. W.Yu, H.Xiao, J.Lin, C.Li. Discovery of Novel STAT3 Small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem 2013;56:4402−12
18. V.M.Shahani, P.Yue, S.Haftchenary,. Identification of purine-scaffold small-molecule inhibitors of stat3 activation by QSAR studies. ACS Med Chem Lett 2011;2:79–84
19. K.H.Leung, L.J.Liu, S.Lin,. Discovery of a small-molecule inhibitor of STAT3 by ligand-based pharmacophore screening. Methods 2015;71:38–43
20. S.Becker, B.Groner, C.W.Muller. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998;394:145−51
21. H.M.Berman, J.Westbrook, Z.Feng,. The Protein Data Bank. Nucleic Acids Res 2000;28:235–42
22. PHASE, version 3.1. New York (NY):Schrödinger LLC; 2009
23. GLIDE, version 5.0. Portland (OR):Schrödinger Inc; 2009
24. M.F.Sanner. Python:a programming language for software integration and development. J Mol Graph Model 1999;17:57–61
25. G.M.Morris, R.Huey, W.Lindstrom,. AutoDock4 and AutoDockTools4:automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91
26. D.A.Case, T.A.Darden, T.E.CheathamIII,. AMBER, version 11. San Francisco (CA):University of California; 2010
27. A.Sali, T.L.Blundell. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779–815
28. D.M.York, T.A.Darden, L.G.Pedersen. The effect of long-range electrostatic interactions in simulations of macromolecular crystals – a comparison of the Ewald and truncated list methods. J Chem Phys 1993;99:8345–8
29. D.Masciocchi, S.Villa, F.Meneghetti,. Biological and computational evaluation of an oxadiazole derivative (MD77) as a new lead for direct STAT3 inhibitors. Med Chem Commun 2012;3:592–9
30. Y.Uehara, M.Mochizuki, K.Matsuno,. Novel high-throughput screening system for identifying STAT3-SH2 antagonist. Biochem Biophys Res Commun 2009;380:627–31
31. J.Turkson, D.Ryan, J.S.Kim,. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276:45443–55
32. T.Tuccinardi, G.Poli, V.Romboli,. Extensive consensus docking evaluation for ligand pose prediction and virtual screening studies. J Chem Inf Model 2014;54:2980−6
33. T.Tuccinardi, G.Poli, M.Dell'Agnello,. Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands. J Enzyme Inhib Med Chem 2015;30:662−70
34. G.Poli, N.Giuntini, A.Martinelli, T.Tuccinardi. Application of a FLAP-consensus docking mixed strategy for the identification of new fatty acid amide hydrolase inhibitors. J Chem Inf Model 2015;55:667–75